Therapeutics News and Research

RSS

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

23 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease.

22 Sep 2014

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

19 Sep 2014

Rosuvastatin drug more effective among prediabetic patients, finds new study

Cardiovascular disease is the leading causes of death worldwide and high cholesterol plays a major role in accelerating its progression. Medical practitioners have turned to statins as a treatment to decrease cholesterol-carrying lipoproteins such as small dense lipoproteins (sdLDL), considered to be especially harmful.

19 Sep 2014

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers.

18 Sep 2014

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease.

18 Sep 2014

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Isis Pharmaceuticals, Inc. announced that it has earned a $4 million milestone payment from Achaogen, Inc. associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF).

16 Sep 2014

Osprey Medical to release enhanced AVERT Plus System at TCT Meeting

Osprey Medical Inc. has developed a new smart syringe and LCD display system, soon to be incorporated with its existing AVERT System.

16 Sep 2014

Blocking bacteria's access to iron: an interview with Dr. Laxminarayana Devireddy

Iron is a key nutrient for nearly all living organisms, including bacteria. Iron is a cofactor for many enzymes necessary for basic metabolic reactions such as DNA synthesis and electron transport. Iron serves as the conduit for the electron transport chain that generates the energy necessary to drive the bacterial cell.

16 Sep 2014

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease.

16 Sep 2014

Six research institutions awarded NIH grants to create database of human cellular responses

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures.

15 Sep 2014

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Discovery reveals promising target for treatment of end-stage heart failure

As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation.

10 Sep 2014

Therapeutics News and Research

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Avalon Ventures, GSK jointly launch two new early-stage life science companies

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Rosuvastatin drug more effective among prediabetic patients, finds new study

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Osprey Medical to release enhanced AVERT Plus System at TCT Meeting

Blocking bacteria's access to iron: an interview with Dr. Laxminarayana Devireddy

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

Six research institutions awarded NIH grants to create database of human cellular responses

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

FDA approves Contrave extended-release tablets for chronic weight management

Discovery reveals promising target for treatment of end-stage heart failure

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News